PTPRC and experimental autoimmune encephalomyelitis: [7] In experimental autoimmune encephalomyelitis, iguratimod directly inhibited myelin basic protein-specific T cell activation and pro-inflammatory cytokine production. [27] Iguratimod also effectively decreased immunoglobulin production by human and mouse B cells and suppressed antibody class switching. [9] In this study, we found that iguratimod significantly reduced the number of B220+ “autoreactive” T cells and plasma cells in the spleen.